Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens

Table 4 Associations between PQ levels and risk of recurrent malaria within 84 days following treatment with AL

Risk factor		Univariate analysis		Multivariate analysis ^b
Risk factor		HR ^a (95% CI)	p-value	HR ^a (95% CI)	p-value
PQ level (ng/ml) at the time malaria diagnosed	<2.5^c (n = 150)	1.0 (reference)	-	1.0 (reference)	-
	2.5 - < 10 (n = 67)	0.80 (0.54-1.17)	0.25	0.83 (0.56-1.24)	0.37
	10 - < 20 (n = 101)	0.65 (0.47-0.89)	0.008	0.67 (0.49-0.93)	0.02
	20 - < 50 (n = 82)	0.50 (0.35-0.72)	<0.001	0.51 (0.36-0.73)	<0.001
	≥50 (n = 25)	0.27 (0.13-0.54)	<0.001	0.30 (0.14-0.63)	0.001

^aHazard ratio adjusted for repeated measures in the same patient.
^bcontrolling for age, pre-treatment parasite density, HIV-exposure, location of residence, household wealth index.
^cBelow the limits of detection.

ISSN: 1475-2875